Compassionate use programme for use of MIS 416 in patients in New Zealand with secondary progressive multiple sclerosis.

Trial Profile

Compassionate use programme for use of MIS 416 in patients in New Zealand with secondary progressive multiple sclerosis.

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 May 2015

At a glance

  • Drugs MIS 416 (Primary)
  • Indications Multiple sclerosis
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 20 May 2015 Results published in an Innate ImmunoTherapeutics media release.
    • 17 Dec 2014 New trial record
    • 12 Dec 2014 Seven patients have recently been added to the compassionate use group, bringing the total number of such patients to 25, according to an Innate Immunotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top